The Company

Endocrine Pharmaceuticals ('Endocrine') of North Hampshire, UK, is a life sciences company with expertise in the hormonal regulation of tissue mass and integrity. Additonal areas of interest are fertility and lifespan.

The company's discovery and research focus, micrin, is a naturally occurring mammalian hormonal inhibitor of tissue masses and an upholder of cellular integrity. Micrin prevents runaway tissue overgrowth and probably inhibits tumour formation and progression as well.

Drug candidates related to micrin are under investigation for therapeutic benefit in a range of benign and malignant tissue overgrowth conditions affecting the pituitary, prostate, breast, heart, kidneys and other tissues, as well as in infertility.

Endocrine optimises operational costs by conducting research through scientists in universities and research institutes in the UK and Australia.

The company's chief executive is Dr John Hart, an endocrinologist by background with significant experience of drug development and exploitation. The company is privately held, by about 80 shareholders.

Endocrine has a professionally constituted Board with technical, legal and commercial expertise, plus an internationally well-regarded Scientific Advisory Board, which includes notable leaders in the fields of endocrinology, physiology and biochemistry.